MRD Clinical Utility Working Group

Girish Putcha, PhD

Consultant

SAGA Diagnostics

Co-Chairs

Melanie Palomares, MD

Senior Medical Director

Exact Sciences

Current Projects

  • Deliverable 1: 

    • A peer-reviewed, published generalizable CU evidence framework

    • Identification and prioritization of intended uses for “archetypal” CU studies (includes literature reviews)

  • Deliverable 2: 

    • Develop consensus on which study design(s) to include within the scope of an initial CU paper (focused on a specific tumor (sub)type, intended use, and assay)

    • Establish workstreams to draft study design “best practices” for each tumor (sub)type and intended use

Participating Organizations

Assocation for Molecular Pathology (AMP), AstraZeneca, Biofidelity Bio-Rad, Bristol Myers Squibb (BMS), Daiichi Sankyo, Delfi Diagnostics, Droplet Biosciences, Eli Lilly, European Organisation for Research and Treatment of Cancer (EORTC), Exact Sciences, Foundation Medicine, GRAIL, GSK, Guardant Health, Illumina, Johnson & Johnson, Labcorp, Lilly, Merck, Natera, NeoGenomics, Personalis, Pfizer, PGDx, Prostate Cancer Clinical Trials Consortium (PCCTC), Quest Diagnostics, SAGA Diagnostics, Tempus, Thermo Fisher Scientific, University of Arkansas for Medical Sciences

Past Deliverables

Not applicable at this time.

Meetings

This working group meets on zoom every other Thursday from 1:00 - 2:00 PM EST.

Special workshops and sessions:

Not applicable.